FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323350870> ?p ?o ?g. }

• W4323350870 endingPage "77" @default.
• W4323350870 startingPage "76" @default.
• W4323350870 abstract "Abstract Background Swallowed topical corticosteroids (STC) are a first-line treatment for eosinophilic esophagitis (EoE) but are not uniformly effective. Dupilumab (DPL), a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation. In Parts A and B of the phase 3 LIBERTY-EoE-TREET (NCT03633617) study, weekly DPL 300mg improved clinical, symptomatic, histologic, and endoscopic aspects of EoE and was generally well tolerated in adult and adolescent patients (pts) with EoE. Purpose To assess the efficacy of weekly DPL 300mg vs placebo (PBO) at Week 24 in pts from Parts A and B with/without prior history of STC use, and from Part B with/without a history of inadequate response, intolerance, or contraindication to STCs. Method Pts who received STCs for EoE within 8 weeks prior to baseline were excluded from the study. Co-primary endpoints at Week 24 were the proportion achieving peak eosinophil count (PEC) ≤6/high-power field (hpf) and the absolute change in Dysphagia Symptom Questionnaire (DSQ) score. Other secondary endpoints at Week 24 included: % change in PEC; absolute change in Histologic Scoring System (HSS) grade and stage scores and Endoscopic Reference Score (EREFS); % change in DSQ score. Result(s) At baseline, in Parts A and B combined, 84/122 (69%) and 87/118 (74%) of DPL- and PBO-treated pts had history of STC use. For pts treated with DPL vs PBO PEC≤6/hpf was achieved by 59.5% vs 3.4% of pts with, and 57.9% vs 12.9% without, prior STC use. Difference vs PBO (95% CI) in the absolute change in DSQ score was −13.27 (−18.03, −8.50) vs −5.21 (−12.41, 2.00) for pts with/without prior STC use. Difference vs PBO (95% CI) for pts with/without prior STC use were: % change in PEC −80.76 (−97.77, −63.75)/−84.87 (−112.16, −57.58); absolute change in EoE-HSS grade −0.77 (−0.87, −0.66)/−0.57 (−0.77, −0.38) and stage −0.77 (−0.87, −0.66)/−0.55 (−0.73, −0.36); absolute change in EREFS −3.86 (−4.70, −3.02)/−2.59 (−4.16, −1.02); % change in DSQ −34.5 (−47.75, −21.22)/-14.9 (−35.21, 5.36). DPL was generally well tolerated in the intent-to-treat population; the most common TEAEs for DPL/PBO were injection-site reactions (37.7/33.3%). In Part B, 38/80 (48%) and 39/79 (49%) of DPL- and PBO-treated pts had inadequate response/intolerance/contraindication to STCs. For DPL vs PBO PEC≤6/hpf was achieved by 55.3% vs 7.7% with, and 61.9% vs 5.0% of pts without, inadequate response/intolerance/contraindication to STC. Difference vs PBO (95% CI) for absolute change in DSQ score was −11.55 (−19.06, −4.04)/−7.08 (−13.75, −0.42) for pts with/without inadequate response/intolerance/contraindication to STCs. Conclusion(s) Conclusion: Regardless of prior STC use, in this pooled analysis from Part A and Part B of the EoE TREET Phase 3 Study, weekly DPL 300mg demonstrated substantial improvements in clinical, histologic, and endoscopic study endpoints at Week 24 in adults and adolescents with EoE. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Disclosure of Interest A. Bredenoord Shareholder of: SST, Grant / Research support from: Bayer, Nutricia, SST, Consultant of: Arena Pharmaceuticals, AstraZeneca, Calypso Biotech, Dr Falk, EsoCap, Gossamer Bio, Laborie, Medtronic, RB Pharma, Regeneron Pharmaceuticals, Inc., Robarts Clinical Trials, E. Dellon Grant / Research support from: Research funding; Adare Pharma Solutions, Allakos, GSK, Meritage Pharma, Miraca Life Sciences, Nutricia, Receptos/BMS, Regeneron Pharmaceuticals, Inc., Shire. Educational grant; Allakos, Banner Pharmaceuticals, Holoclara, Consultant of: Abbott, Adare Pharma Solutions, Aimmune Therapeutics, Alivio Therapeutics, Allakos, Arena Pharmaceuticals, AstraZeneca, Banner Pharmaceuticals, Biorasi, Calypso Biotech, Enumeral, EsoCap, Gossamer Bio, GSK, Receptos/BMS, Regeneron Pharmaceuticals, Inc., Robarts Clinical Trials, Salix Pharmaceuticals, Shire/Takeda, A. Lucendo Grant / Research support from: Dr Falk, Regeneron Pharmaceuticals, Inc., Consultant of: Dr Falk, EsoCap, M. Collins Grant / Research support from: Receptos/BMS, Regeneron Pharmaceuticals, Inc., Shire, Consultant of: Allakos, AstraZeneca, BMS, EsoCap, Regeneron Pharmaceuticals, Inc., Shire, A. Khodzhayev Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., X. Sun Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., K. Patel Employee of: Sanofi, B. Beazley Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc., A. Shabbir Shareholder of: Regeneron Pharmaceuticals, Inc., Employee of: Regeneron Pharmaceuticals, Inc." @default.
• W4323350870 created "2023-03-08" @default.
• W4323350870 creator A5003154635 @default.
• W4323350870 creator A5004180518 @default.
• W4323350870 creator A5012642973 @default.
• W4323350870 creator A5018454677 @default.
• W4323350870 creator A5021092520 @default.
• W4323350870 creator A5033969727 @default.
• W4323350870 creator A5035878576 @default.
• W4323350870 creator A5056364928 @default.
• W4323350870 creator A5058290389 @default.
• W4323350870 date "2023-03-01" @default.
• W4323350870 modified "2023-09-28" @default.
• W4323350870 title "A141 DUPILUMAB IMPROVES CLINICAL, SYMPTOMATIC, ENDOSCOPIC, AND HISTOLOGIC ASPECTS OF EOE, REGARDLESS OF PRIOR SWALLOWED TOPICAL STEROID USE" @default.
• W4323350870 doi "https://doi.org/10.1093/jcag/gwac036.141" @default.
• W4323350870 hasPublicationYear "2023" @default.
• W4323350870 type Work @default.
• W4323350870 citedByCount "0" @default.
• W4323350870 crossrefType "journal-article" @default.
• W4323350870 hasAuthorship W4323350870A5003154635 @default.
• W4323350870 hasAuthorship W4323350870A5004180518 @default.
• W4323350870 hasAuthorship W4323350870A5012642973 @default.
• W4323350870 hasAuthorship W4323350870A5018454677 @default.
• W4323350870 hasAuthorship W4323350870A5021092520 @default.
• W4323350870 hasAuthorship W4323350870A5033969727 @default.
• W4323350870 hasAuthorship W4323350870A5035878576 @default.
• W4323350870 hasAuthorship W4323350870A5056364928 @default.
• W4323350870 hasAuthorship W4323350870A5058290389 @default.
• W4323350870 hasBestOaLocation W43233508701 @default.
• W4323350870 hasConcept C126322002 @default.
• W4323350870 hasConcept C141071460 @default.
• W4323350870 hasConcept C142724271 @default.
• W4323350870 hasConcept C16005928 @default.
• W4323350870 hasConcept C204232928 @default.
• W4323350870 hasConcept C204787440 @default.
• W4323350870 hasConcept C27081682 @default.
• W4323350870 hasConcept C2776042228 @default.
• W4323350870 hasConcept C2779134260 @default.
• W4323350870 hasConcept C2779824493 @default.
• W4323350870 hasConcept C2779929431 @default.
• W4323350870 hasConcept C2780596822 @default.
• W4323350870 hasConcept C2781065132 @default.
• W4323350870 hasConcept C71924100 @default.
• W4323350870 hasConcept C90924648 @default.
• W4323350870 hasConceptScore W4323350870C126322002 @default.
• W4323350870 hasConceptScore W4323350870C141071460 @default.
• W4323350870 hasConceptScore W4323350870C142724271 @default.
• W4323350870 hasConceptScore W4323350870C16005928 @default.
• W4323350870 hasConceptScore W4323350870C204232928 @default.
• W4323350870 hasConceptScore W4323350870C204787440 @default.
• W4323350870 hasConceptScore W4323350870C27081682 @default.
• W4323350870 hasConceptScore W4323350870C2776042228 @default.
• W4323350870 hasConceptScore W4323350870C2779134260 @default.
• W4323350870 hasConceptScore W4323350870C2779824493 @default.
• W4323350870 hasConceptScore W4323350870C2779929431 @default.
• W4323350870 hasConceptScore W4323350870C2780596822 @default.
• W4323350870 hasConceptScore W4323350870C2781065132 @default.
• W4323350870 hasConceptScore W4323350870C71924100 @default.
• W4323350870 hasConceptScore W4323350870C90924648 @default.
• W4323350870 hasIssue "Supplement_1" @default.
• W4323350870 hasLocation W43233508701 @default.
• W4323350870 hasLocation W43233508702 @default.
• W4323350870 hasOpenAccess W4323350870 @default.
• W4323350870 hasPrimaryLocation W43233508701 @default.
• W4323350870 hasRelatedWork W2021043993 @default.
• W4323350870 hasRelatedWork W2038449916 @default.
• W4323350870 hasRelatedWork W2115407619 @default.
• W4323350870 hasRelatedWork W2123896274 @default.
• W4323350870 hasRelatedWork W2403960492 @default.
• W4323350870 hasRelatedWork W2591530977 @default.
• W4323350870 hasRelatedWork W2605569130 @default.
• W4323350870 hasRelatedWork W2801955994 @default.
• W4323350870 hasRelatedWork W305378111 @default.
• W4323350870 hasRelatedWork W4316082282 @default.
• W4323350870 hasVolume "6" @default.
• W4323350870 isParatext "false" @default.
• W4323350870 isRetracted "false" @default.
• W4323350870 workType "article" @default.